PharmaTher Updates on FDA Ketamine Application

PharmaTher Holdings Ltd (TSE:PHRM) has released an update.

PharmaTher Holdings Ltd. has scheduled a meeting with the FDA for December 2, 2024, to address minor deficiencies in its ketamine drug application. The FDA has classified these deficiencies as minor, requiring new and updated information related to manufacturing and microbiology, but no additional preclinical or clinical studies are needed.

For further insights into TSE:PHRM stock, check out TipRanks’ Stock Analysis page.